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Abstract
Background: Treatment of cells with the anti-cancer drug 5-fluorouracil (5-FU) causes DNA damage, which in
turn affects cell proliferation and survival. Two stable wild-type TP53 5-FU-resistant cell lines, ContinB and
ContinD, generated from the HCT116 colon cancer cell line, demonstrate moderate and strong resistance to 5-
FU, respectively, markedly-reduced levels of 5-FU-induced apoptosis, and alterations in expression levels of a
number of key cell cycle- and apoptosis-regulatory genes as a result of resistance development. The aim of the
present study was to determine potential differential responses to 8 and 24-hour 5-FU treatment in these
resistant cell lines. We assessed levels of 5-FU uptake into DNA, cell cycle effects and apoptosis induction
throughout treatment and recovery periods for each cell line, and alterations in expression levels of DNA damage
response-, cell cycle- and apoptosis-regulatory genes in response to short-term drug exposure.
Results: 5-FU treatment for 24 hours resulted in S phase arrests, p53 accumulation, up-regulation of p53-target
genes on DNA damage response (ATF3, GADD34, GADD45A, PCNA), cell cycle-regulatory (CDKN1A), and
apoptosis-regulatory pathways (FAS), and apoptosis induction in the parental and resistant cell lines. Levels of 5-
FU incorporation into DNA were similar for the cell lines. The pattern of cell cycle progression during recovery
demonstrated consistently that the 5-FU-resistant cell lines had the smallest S phase fractions and the largest G2(/
M) fractions. The strongly 5-FU-resistant ContinD cell line had the smallest S phase arrests, the lowest CDKN1A
levels, and the lowest levels of 5-FU-induced apoptosis throughout the treatment and recovery periods, and the
fastest recovery of exponential growth (10 days) compared to the other two cell lines. The moderately 5-FU-
resistant ContinB cell line had comparatively lower apoptotic levels than the parental cells during treatment and
recovery periods and a recovery time of 22 days. Mitotic activity ceased in response to drug treatment for all cell
lines, consistent with down-regulation of mitosis-regulatory genes. Differential expression in response to 5-FU
treatment was demonstrated for genes involved in regulation of nucleotide binding/metabolism (ATAD2, GNL2,
GNL3, MATR3), amino acid metabolism (AHCY, GSS, IVD, OAT), cytoskeleton organization (KRT7, KRT8, KRT19,
MAST1), transport (MTCH1, NCBP1, SNAPAP, VPS52), and oxygen metabolism (COX5A, COX7C).
Conclusion: Our gene expression data suggest that altered regulation of nucleotide metabolism, amino acid
metabolism, cytoskeleton organization, transport, and oxygen metabolism may underlie the differential resistance
to 5-FU seen in these cell lines. The contributory roles to 5-FU resistance of some of the affected genes on these
pathways will be assessed in future studies.
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5-fluorouracil is a chemotherapeutic drug used worldwide
in the treatment of metastatic colorectal cancer, either
alone or in combination with irinotecan, a topoisomerase
I inhibitor. 5-FU is considered to be purely an S phase-
active chemotherapeutic agent, with no activity when cells
are in G0 or G1 [1]. It is well-established that treatment of
cells with 5-FU causes DNA damage, specifically double-
strand (and single-strand) breaks, during S phase due to
the misincorporation of FdUTP into DNA [2,3]. However,
damage to DNA can occur in all cell cycle phases in prolif-
erating cells, and the repair mechanisms involved vary in
the different phases of the cell cycle [4,5]. DNA damage
checkpoint pathways in G1, S, and G2 couple DNA dam-
age detection to inhibition of cell cycle progression, acti-
vation of DNA repair, maintenance of genomic stability,
and when damage is beyond repair, to initiation of cellu-
lar senescence [6].
The position of tumor cells in the cell cycle and the ability
to undergo apoptosis in response to drug treatment
together play an important role in the sensitivity of tumor
cells to chemotherapy. 5-FU has a complicated mecha-
nism of action with several enzymes involved in its meta-
bolic activation [7]. It inhibits thymidylate synthase as its
main mechanism of action, leading to depletion of dTTP.
Overexpression of thymidylate synthase has been shown
to be associated with 5-FU resistance in colorectal cancer
[8,9], but it is also likely that other alterations, for exam-
ple, to crucial genes on cell cycle and apoptotic regulatory
pathways, underlie the development of resistance. Two
independent 5-FU-resistant cell lines, designated ContinB
and ContinD, were recently generated from parental
HCT116 colon cancer cells via continuous exposure to 5-
FU, and characterized for genotypes, phenotypes, and
gene expression associated with the generation of 5-FU
resistance [10]. Compared to parental HCT116 cells, the
resistant cell lines demonstrated moderate (ContinB) to
strong (ContinD) resistance to 5-FU and up-regulation of
TYMS. Cellular phenotypes such as reduced apoptosis and
more aggressive growth relative to the parental HCT116
cell line characterized both resistant cell lines. This was
consistent with up-regulation of apoptosis-inhibitory
genes (IRAK1, MALT1, BIRC5), positive growth-regula-
tory genes (CCND3, CCNE2), DNA repair genes (FEN1,
FANCG), and metastasis signature genes (LMNB1, F3
TMSNB), and down-regulation apoptosis-promoting
genes (BNIP3, BNIP3L, FOXO3A) and negative growth-
regulatory genes (AREG, CDKN1A, CCNG2, GADD45A)
in one or both resistant cell lines. Both 5-FU-resistant cell
lines retained the wild-type TP53 genotype characteristic
of the parental HCT116 cells [10]. In the present work, the
cellular responses of HCT116 parental and 5-FU-resistant
cell lines to short-term 5-FU treatment were characterized
and compared. Given the fact that the 5-FU-resistant cell
lines displayed reduced apoptosis and more aggressive
growth phenotypes compared to the parental cells as a
consequence of resistance development, it was of interest
to determine potential differential responses to 5-FU dur-
ing short-term 5-FU challenge. We investigated cell cycle
effects and apoptosis induction throughout treatment and
recovery periods for each cell line, as well as changes in
expression levels of DNA damage response-, cell cycle-
and apoptosis-regulatory genes (among others) that occur
within the first 24 hours in response to 5-FU treatment.
Characterizations of the cellular responses to short-term
drug treatment in resistant colorectal cancer cells will
facilitate a better understanding of the multiple mecha-
nisms involved in drug response and development of 5-
FU resistance.
Results
Cell proliferation, cell cycle distribution, and apoptosis 
during recovery from 5-FU treatment
Cells were treated with 5-FU for 24 hours and followed for
up to 40 days in drug-free medium to determine cell
counts, cell cycle distributions, and apoptotic fractions
(Figure 1). Cell counts decreased during the early period
of recovery following drug removal (up to and including
day 6) for all cell lines, after which point they flattened
out for the parental and ContinB cells (Figure 1). After day
7, the cell counts for ContinD increased steadily. The cell
counts for ContinB and parental cultures began to
increase after about 15 and 20 days, respectively.
Cell cycle analyses were performed to elucidate the pat-
terns and timeframes of cell cycle progression during
recovery in each 5-FU-treated cell line (Figure 2). After an
initial accumulation in S phase during the first 24 hours
with drug treatment (see later), the S phase fractions
decreased in all cell lines during the early period of recov-
ery following drug removal, concomitant with increases
in the G1 and G2/M fractions. Overall, the 5-FU-resistant
cell lines had the smallest S phase fractions (Figure 2b),
and in the case of the ContinD cell line, the largest G2/M
fractions (Figure 2c). The S phase fractions increased again
at 8 and 15 days for ContinD and ContinB cells, respec-
tively. The cell cultures were eventually allowed to reach
full confluence, evidenced by an increase in the G1 frac-
tion and decreases in the S and G2/M phase fractions in all
the cell lines.
5-FU-induced DNA damage resulted in large differences
in apoptosis induction in the HCT116 cell lines during
treatment and recovery (Figure 3), with the highest levels
of apoptosis observed in the parental cells and the lowest
in the ContinD cells. Following removal of 5-FU at 24
hours, apoptosis levels increased in the parental and Con-
tinB cells, until they peaked at over 80% on day 10, after
which they decreased to 30%. On day 15 the apoptoticPage 2 of 25
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cells, peaking at about 80% on day 20, and then the levels
gradually decreased to control levels at day 24. There was
no 5-FU induced increase in the fraction of apoptotic
ContinD cells (compared to the levels of spontaneous
apoptosis in the untreated cells).
5-FU incorporation and cell cycle progression during the 
initial 24 hour treatment period
The large differences in cell growth and apoptosis during
recovery suggested that there might be differential
responses to 5-FU in the cell lines during the first 24 hours
of treatment. The reduced apoptosis of ContinB/D cells to
5-FU compared to the parental cells could have been due
to decreased incorporation of 5-FU into DNA. At 8 hours,
the parental cell line incorporated more [6-3H]5-FU into
DNA than did either of the resistant cell lines, but the dif-
ferences were not significant (Figure 4). At 24 hours, the
ContinD cell line showed the highest levels of 5-FU incor-
poration into DNA, whereas the ContinB cell line had the
lowest levels (p < 0.05). However, neither of the two
resistant cell lines showed significant differences in incor-
poration relative to the parental cells.
We further investigated whether there were differences in
growth or cell cycle progression during the first 24 hours
of 5-FU treatment. The growth of HCT116 parental cells
was completely inhibited at 24 hours (Figure 5). The cell
number increased after 24 hours of 5-FU treatment for the
ContinD and to a smaller degree for the ContinB cell
lines, but less than in the corresponding controls. How-
ever, since the fraction of apoptotic cells was increased at
24 hours for the parental (and to a smaller degree ContinB
cells; Figure 3), some cells in these cultures may still have
divided during the 24 hour period, in agreement with the
non-zero mitotic fractions observed at 8 hours (Figure 6).
No mitotic cells were observed at 24 hours. The distribu-
tion of cells in the G1, S, and G2(/M) phases of the cell
cycle was measured by staining for DNA content (Figure
7). A G1(/S) arrest occurred in the parental and ContinB
cells at 8 hours after 5-FU addition, evidenced by a larger
fraction of cells in the G1 phase. At 8 hours, the size of the
G1 fraction in 5-FU-treated ContinD cells was similar to
that measured for its untreated control. S phase fractions
in all 5-FU-treated cell lines were equivalent in size and
similar to those measured in the respective untreated con-
trols at the 8 hour timepoint. The sizes of the G2(/M) frac-
Cell counts during recovery periods following drug removalFigure 1
Cell counts during recovery periods following drug removal: cell counts were measured throughout the respective 
recovery periods for each cell line following a shift to drug-free medium at 24 hours (Day 1). The dashed (---) line shows the 
number of viable cells in untreated exponentially-growing cultures.
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Cell cycle distributions during recovery periods following drug removalFigure 2
Cell cycle distributions during recovery periods following drug removal: fractions of cells in (a)G1, (b)S, and (c)G2
cell cycle phases were measured at intervals during the   respective recovery periods for each cell line.
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Molecular Cancer 2006, 5:20 http://www.molecular-cancer.com/content/5/1/20tions in 5-FU-treated parental and ContinB cell lines were
smaller than their respective controls at 8 hours, but in
ContinD cells the size of the G2 fraction was similar to that
measured for the untreated controls. At 24 hours, the G1
fractions in all 5-FU-treated cell lines were smaller and the
S phase fractions were larger compared to their respective
untreated controls, indicating release of the arrested cells
at the G1/S boundary and movement into S phase. The cell
cycle histograms show directly synchronized populations
of cells in S phase caused initially by the G1/S arrest and
subsequent release of these cells into S phase (Figure 7).
Parental HCT116 cells had the largest S phase accumula-
tion (80% S phase cells), whereas ContinB and ContinD
cells had smaller S phase accumulations (70% and 52%,
respectively) compared to 25% in the respective untreated
controls (Figure 7c). The G2 fractions in the 5-FU-treated
cells at 24 hours were smaller relative to those measured
for untreated control cells, probably reflecting the slow
movement of cells through S phase. ContinD cells had the
largest G2 fraction compared to the other 5-FU-treated cell
lines.
Expression of DNA damage response, cell-cycle regulatory, 
and apoptosis-regulatory genes
Since neither the incorporation of 5-FU nor differences in
cell cycle arrest could explain the large differences in 5-FU
resistance and induction of apoptosis, we investigated the
gene expression patterns of the cell lines in response to 5-
FU challenge. Table 1 summarizes the microarray gene
expression data for altered genes localized to DNA dam-
age response, cell cycle-regulatory and apoptosis-regula-
tory pathways. The alterations in gene expression levels
are in response to 5-FU treatment, but information about
whether these genes were altered as a consequence of
resistance development [10] are also included. For some
genes, protein levels were measured in addition to gene
transcript levels at 8 and 24 hours (Figure 8). At 8 hours,
p53 protein levels were 2.0, 1.8, and 1.4 fold higher in 5-
FU-treated parental, ContinB and ContinD cells respec-
tively relative to their respective untreated controls (Figure
8a). At 24 hours, p53 protein levels had increased further
relative to control levels; levels were 2.3, 3.0, and 2.1-fold
higher in 5-FU-treated parental, ContinB and ContinD
cells respectively. A number of important genes located on
DNA damage response pathways were scored as altered in
the 5-FU-treated cells relative to the untreated control cells
following exposure to 5-FU. The ATF3, GADD34,
GADD45A, PCNA, and TP53I3 genes were all up-regulated
at 8 and/or 24 hours in response to 5-FU treatment in all
HCT116 cell lines relative to untreated controls.
GADD45A transcript levels were highest in 5-FU-treated
ContinB cells at 24 hours, nearly 10-fold higher than in
the untreated control. (GADD45A expression levels meas-
ured by real-time RT-PCR correlated well with those meas-
ured using the 13 K microarrays (r = 0.83, p < 0.05)).
However, GADD45A protein levels increased only 10% in
the treated parental and ContinB cell lines at 8 hours, and
in ContinD cells they had actually decreased about 10%;
Apoptotic fractions during recovery periods following drug removalFigure 3
Apoptotic fractions during recovery periods following drug removal: apoptosis induction in 5-FU-treated HCT116 
cell lines during the respective recovery periods for each cell line. The dashed line shows the levels of natural (spontaneous) 
apoptosis in untreated control cells.
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Molecular Cancer 2006, 5:20 http://www.molecular-cancer.com/content/5/1/20at 24 hours there was no change in GADD45A protein lev-
els in the treated parental cells, whereas we measured a
decrease of 1.3 and 1.8 fold respectively for treated Con-
tinB and ContinD relative to their respective controls (Fig-
ure 8b). RAD23A and XPC were down-regulated and up-
regulated respectively in ContinB cells at 8 hours, but not
in the other cell lines at any timepoint. MSH2 was down-
regulated in the 5-FU-treated parental and ContinB cell
lines.
Cell cycle alterations at 8 and 24 hours after drug addition
were reflected in altered expression patterns of genes
involved in cell cycle progression in the treated HCT116
cell lines compared to untreated controls. Cell cycle- and
growth-regulatory genes such as AREG, CCND3 and
CDKN1A were up-regulated in all 5-FU-treated cell lines
compared to untreated controls at either 8 or 24 hours or
both, whereas down-regulation of CCNB1 was detected in
ContinD cells only. CCNC, CCNG1, and CDC25B were
down-regulated in parental and ContinB cells, whereas
RAN was down-regulated in ContinB cells (Table 1).
There was good correlation between CDKN1A expression
measured by real-time RT-PCR and that measured using
the 13 K microarrays (r = 0.7, p < 0.05). CDKN1A protein
levels at 8 hours were 1.9, 2.6, and 1.7-fold higher in the
treated parental, ContinB, and ContinD cells respectively
relative to their untreated controls, whereas the corre-
sponding levels were 2.8, 3.8 and 2.0-fold higher at 24
hours (Figure 8c). MYC was also induced in response to 5-
FU treatment in all HCT116 cell lines; protein levels at 8
hours were 2.3, 2.4, and 3.2 fold higher in the treated
parental, ContinB and ContinD cells, respectively com-
pared to their untreated controls, and at 24 hours, these
levels had increased 2.9, 2.4 and 4.8-fold compared to
their respective controls (Figure 8d). MYC protein levels
did not correlate with transcript levels, since the MYC
transcript was down-regulated in parental and ContinB
cell lines (slight down-regulation in ContinD cells) (Table
1). The cell cycle-regulatory genes CDC6, CDCA5, PDAP1,
PDXP, PVT1, and RARRES2 were altered in the parental
HCT116 cell line but not in either of the 5-FU-resistant
cell lines in response to short-term drug treatment. The S-
phase regulatory gene PPP2CB was up-regulated in all cell
lines, whereas RRM2 was up-regulated in parental and
ContinB cells. MCM3 was down-regulated in all cell lines,
consistent with reduction or cessation of replication activ-
ity. In agreement with the reduced entry into mitosis,
spindle-checkpoint and mitosis-regulatory genes such as
BUB1, BUB1B, NEK4, PLK and STK6 were all down-regu-
lated at 8 and/or 24 hours in these cell lines in response
to 5-FU.
Incorporation of 5-FU into DNA of parental and 5-FU-resistant HCT116 cell lines in response to 8 and 24-hr. 5-FU treatmentFigure 4
Incorporation of 5-FU into DNA of parental and 5-FU-resistant HCT116 cell lines in response to 8 and 24-hr. 5-
FU treatment: Incorporation of 5-FU into DNA is given as the ratio of disintegrations per minute (dpm) per μg DNA. The 
dashed line represents background dpm levels.
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Cell growth in parental and 5-FU-resistant HCT116 cell lines in response to 5-FU treatment for 24 hoursFigure 5
Cell growth in parental and 5-FU-resistant HCT116 cell lines in response to 5-FU treatment for 24 hours: cell 
growth at 8 and 24 hours after addition of 5-FU to the media in (a) parental cells, (b) ContinB cells, (c) ContinD cells.
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Molecular Cancer 2006, 5:20 http://www.molecular-cancer.com/content/5/1/20Table 1 summarizes the expression levels of apoptosis-reg-
ulatory genes that were altered at 8 and 24 hours follow-
ing drug addition in the HCT116 parental and resistant
cell lines. The apoptosis-inhibiting genes AVEN and
SERPINB2 were up-regulated at both 8 and 24 hours. The
p53-regulated apoptosis-promoting gene FAS was up-reg-
ulated in each cell line, but lowest FAS levels were seen in
ContinD cells. The apoptosis-promoting gene BNIP3L
was down-regulated in all cell lines, while the apoptosis-
promoting gene CASP3 was down-regulated in ContinB
cells only.
Some of the genes whose expression levels had been
altered as a consequence of resistance development were
further altered in response to short-term 5-FU treatment
(8 or 24 hrs.) (Table 1), e.g. AREG, ATF3, BNIP3L,
CCND3, CCNG1, CDKN1A, CHC1, GADD45A, MCM3,
PLK, and STK6. Interestingly, some genes that were ini-
tially down-regulated as a result of resistance develop-
ment (AREG, CDKN1A, GADD45A) were up-regulated in
response to short-term 5-FU treatment. The opposite was
also true; some genes that were initially up-regulated as a
result of resistance development (CHC1, MCM3, PLK, and
STK6) were down-regulated in response to short-term
drug treatment.
Differences in 5-FU-induced gene expression in 5-FU-
resistant cell lines
Having discussed genes specifically involved in DNA
damage response, cell cycle and apoptosis regulation, we
next focused on the genes that showed the largest differ-
ences in 5-FU-induced expression in the cell lines with dif-
ferent resistance levels (Table 2). A set of genes coding for
guanine nucleotide-binding proteins (G proteins), which
integrate signals between membrane receptors and down-
stream effector proteins, showed marked differential
expression after 5-FU treatment in the 5-FU-resistant cell
lines. GNL3 was only down-regulated in ContinD cells,
while GNL2 was only down-regulated in ContinB cells.
Neither of them were altered in the parental cell line in
response to 5-FU. Other genes involved in nucleoside/
nucleotide metabolism were also differentially expressed.
ATAD2 was down-regulated in ContinD cells, whereas
CMPK, MATR3, PRPS2 and TNRC8 were altered in Con-
tinB cells. Genes involved in mRNA processing/transport
(e.g. EPRS, GNB2, STAU1, SYMPK) were down-regulated
in the parental cell line but not in the resistant cell lines.
Other differentially-expressed genes were involved in reg-
ulation of cytoskeleton organization and cell adhesion:
KRT7, KRT8, KRT19, all up-regulated in ContinB cells;
JUP, up-regulated in ContinD cells and down-regulated in
Mitotic fractions in parental and 5-FU-resistant HCT116 cell lines in response to 5-FU treatment for 24 hoursFigure 6
Mitotic fractions in parental and 5-FU-resistant HCT116 cell lines in response to 5-FU treatment for 24 hours: 
mitotic fractions in all cell lines at 8 and 24 hours after 5-FU addition, showing gradual cessation of mitosis over the 24-hour 
treatment period.
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Molecular Cancer 2006, 5:20 http://www.molecular-cancer.com/content/5/1/20ContinB cells; ACTG2, ARPC3, F2, down-regulated in
parental cells. Genes involved in amino acid metabolism
(e.g. AHCY, GSS, IVD, OAT) were all down-regulated in
ContinB cells. Signal transduction and transport genes
such as NCBP1, RAN, SNAPAP, TM9SF2 were down-regu-
lated in ContinB cells, whereas CENTG3 and TAX1BP1
were altered in ContinD cells. VPS52 was down-regulated
in parental HCT116 cells. Some of the genes whose
expression levels were altered in response to short-term 5-
FU treatment had also been altered as a consequence of
resistance development, e.g. IVD and TAX1BP1.
Discussion
Cell cycle progression after DNA damage is regulated by
checkpoint controls in the G1 or G2 phase of the cell cycle.
Additionally, S phase progression is reduced, but not
entirely halted, after DNA damage [11]. Arrest in G1 and
G2 allows repair prior to replication and mitosis, respec-
tively.
Failure to repair can result in apoptosis, mitotic catastro-
phe, or senescence [6]. In the present work, we wanted to
elucidate potential differential responses to 8 and 24-hour
5-FU treatment in the HCT116 parental cell line and its 5-
FU-resistant derivatives. We assessed several cellular phe-
notypes in an effort to clarify potential differences: levels
of 5-FU uptake into DNA, cell cycle effects and apoptosis
induction throughout treatment and recovery periods for
each cell line. Each cell line incorporated 5-FU into DNA,
but levels of incorporation were not significantly different
between the cell lines at either 8 or 24 hours. 5-FU led to
a G1(/S) arrest at 8 and 24 hours, consistent with the
results of previous studies [7,12,13]. The G1 arrest was
most pronounced in ContinD cells at 24 hours, whereas
Cell cycle progression in parental and 5-FU-resistant HCT116 cell lines in response to 5-FU treatment for 24 hoursFigure 7
Cell cycle progression in parental and 5-FU-resistant HCT116 cell lines in response to 5-FU treatment for 24 
hours: (a) cell cycle distributions showing G1/S boundary arrests at 8 hours and S phase arrests at 24 hours, showing S phase 
arrests at 24 hours; (b)-(d) G1, S and G2M fractions in all cell lines at 8 and 24 hours after 5-FU addition.
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Molecular Cancer 2006, 5:20 http://www.molecular-cancer.com/content/5/1/20Table 1: Differential gene expression in parental HCT116 and 5-FU-resistant cell lines: DNA damage response/repair, cell cycle, and 
apoptosis regulatory pathways.
Gene 
symbol
parent al 8 
hr 5 FUa
parenta l 24 
hr 5 FU a
Contin B 8 
hr 5 FU a
Contin B 24 
hr 5 FU a
Contin D 8 
hr 5 FU a
Contin D 24 
hr 5 FU a
altered in 
ContinB as 
a result of 
resistance 
developmen
t b
altered in 
ContinD as 
a result of 
resistance 
developmen
t b
Regulatory 
pathway/
function
DNA 
damage 
response/
DNA repair
ATF3 2.1 3.1 1.5 2.3 1.8 2.8 -0.7 -1.2 protective 
response of 
human cells 
to ionizing 
radiation
GADD34 0.9 1.4 0.9 1.3 0.8 1.5 -0.1 -0.2 cellular 
response to 
stress and 
DNA 
damage 
stressful 
growth 
arrest 
conditions, 
treatment 
with DNA-
damaging
GADD45A 2.3 2.9 2.8 3.1 1.5 2.1 -1.1 -0.3 agents
MMS2 0.3 0.7 0.2 0.6 -0.1 -0.1 na na cellular 
response to 
stress; 
regulation 
of DNA 
repair
MSH2 -1.0 -1.1 -1.2 -0.7 -0.2 -0.8 -0.3 0.8 mismatch 
repair
PCNA 1.1 2.6 0.9 2.2 0.6 1.3 0.8 0.8 involved in 
DNA 
replication 
and repair
RAD23A -0.2 -0.4 -1.6 -0.5 -0.1 0.1 na na nucleotide 
excision 
repair
TP53 -0.8 -1.0 0.0 -0.9 0.0 -0.5 0.5 0.4 DNA 
damage 
response, 
negative 
regulator of 
cell growth
TP53I3 -0.7 2.3 0.7 2.5 0.4 2.5 na na cellular 
response to 
oxidative 
stresses and 
irradiation
XPC 0.0 0.4 1.3 0.8 0.2 0.5 -0.6 -0.4 nucleotide 
excision 
repair
Cell cycle/
cell 
proliferatio
nPage 10 of 25
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regulator of 
cell growth; 
inhibits 
apoptosis 
together 
with IGF1
BUB1 -1.3 -1.1 -0.6 -0.3 -0.5 -0.9 0.4 0.6 spindle 
checkpoint 
function
BUB1B -1.4 -2.5 -0.9 -1.8 -0.9 -1.4 0.6 0.6 spindle 
checkpoint 
function
CCNB1 -0.3 -0.5 -0.5 -0.4 -0.5 -1.8 na na regulates 
G2M cell 
cycle 
transition
CCNB2 -0.7 -1.1 -0.7 -0.7 -0.4 -1.6 0.0 0.5 regulates 
G2M cell 
cycle 
transition
CCNC -1.0 -1.9 -2.1 -2.0 -0.4 -0.5 -0.4 -0.3 involved in 
G1 cell cycle 
regulation
CCND3 0.7 1.6 0.9 2.4 0.4 1.0 1.7 0.1 regulates 
G1/S cell 
cycle 
transition
CCNG1 -1.8 -1.1 -0.4 -1.3 -0.3 -0.5 -1.4 -0.3 growth 
inhibitory 
activity 
linked to 
ARF-p53 
and pRb 
pathways.
CDC25B -1.6 -1.4 -0.9 -1.2 -0.3 -0.6 0.2 -0.7 dephosphor
ylates 
CDC2 to 
allow 
progression 
to mitosis
CDC6 0.7 1.1 -0.6 0.0 0.2 0.2 0.8 1.0 regulator at 
early steps 
of DNA 
replication
CDCA5 0.2 1.4 -0.1 0.5 0.2 0.2 na na G1/S 
transition of 
cell cycle
CDKN1A 2.4 3.1 2.8 3.6 1.9 3.0 -0.5 -1.1 negative 
regulator of 
cell cycle 
progression 
at G1
CHC1 -1.5 -0.2 -1.4 -1.1 -0.4 -0.2 1.8 0.7 regulator of 
chromosom
e 
condensatio
n
GTF2B -0.7 -0.4 -1.1 -1.3 -0.2 0.2 -0.8 -0.1 regulation 
of 
transcriptio
n, DNA-
dependent
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e 
organization 
and 
biogenesis; 
nucleosome 
assembly
IRF6 -0.3 0.5 -0.6 0.1 0.0 1.2 na na regulation 
of 
transcriptio
n, DNA-
dependent
LIPH 0.2 -1.2 -0.5 -0.4 0.0 0.0 na na stimulation 
of cell 
proliferation 
and motility
MCM3 -0.6 -1.5 -0.4 -2.1 0.0 -1.9 1.0 0.8 initiation of 
genome 
replication; 
formation of 
replication 
forks
MKI67 -0.8 -1.2 0.0 -0.4 -0.1 -0.4 0.8 0.9 antigen 
identified by 
monoclonal 
antibody Ki-
67; cell 
proliferation
MYC -0.3 -1.2 -1.1 -1.9 -0.6 -0.2 -0.3 -0.5 dual 
signaling for 
cell growth 
and cell 
death
NAP1L1 -0.3 -0.8 -0.9 -1.9 -0.4 -0.7 na na DNA 
replication; 
positive 
regulation 
of cell 
proliferation
NBL1 -1.1 -1.3 -0.7 -0.5 0.0 -0.1 na na transcriptio
n factor; 
negative 
regulator of 
cell cycle
NDEL1 -0.6 -0.3 -1.5 -1.1 -0.3 0.0 0.3 -0.1 thiol-
activated 
peptidase 
phosphoryla
ted in M 
phase of the 
cell cycle
NEK1 -0.7 -1.2 -0.2 0.0 -0.1 -0.5 na na DNA 
damage 
response 
pathway at 
the G2/M 
transition
NEK4 -1.0 -1.2 -0.6 -0.8 -0.5 -1.2 na na involved in 
mitosis
NEK9 -1.2 -1.1 nd -0.1 -0.2 -0.4 na na binds Ran 
GTPase and 
regulates 
mitotic 
progression
Table 1: Differential gene expression in parental HCT116 and 5-FU-resistant cell lines: DNA damage response/repair, cell cycle, and 
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cell division; 
establishme
nt/
maintenance 
of cell 
polarity
PDAP1 0.2 -1.3 0.5 -0.3 0.2 -0.5 0.9 0.8 cell 
proliferation
; signal 
transductio
n
PDXP -0.3 -1.3 0.4 -0.3 0.1 -0.5 na na maintaining 
biochemical 
homeostasis 
required for 
proper 
spindle 
assembly/
function; 
regulates 
G2M
PLK -2.1 -2.3 -1.8 -2.8 -0.5 -1.6 1.5 0.7 progression
PPP2CB 0.8 1.7 1.0 2.2 0.2 1.1 0.1 0.0 negative 
regulator of 
cell growth 
and division
PVT1 -1.4 -0.7 0.6 0.4 0.1 0.4 na na MYC 
activator
RAN -0.6 -0.8 -1.2 -1.6 0.0 -0.3 0.0 0.2 translocatio
n of RNA 
and proteins 
through 
nuclear 
pore 
complex
RARRES2 -1.6 -0.9 -0.1 -0.6 -0.1 -0.1 nd nd growth 
inhibitory 
and cell 
differentiati
on activities
RFP -0.6 -0.4 -1.0 -1.1 -0.1 0.2 na na cell 
proliferation
; regulation 
of 
transcriptio
n, DNA-
dependent
RNF4 -0.2 -1.1 0.1 -0.4 -0.1 0.1 0.3 0.2 transcriptio
n regulator; 
inhibits 
activity of 
TRPS1
RRM2 0.9 1.4 0.9 1.0 0.4 0.1 0.4 0.8 catalyzes 
formation of 
deoxyribon
ucleotides 
from 
ribonucleoti
des
RUNX3 -0.7 -0.8 -0.6 -1.3 -0.1 0.0 0.1 -0.3 cell 
proliferation
; regulation 
of 
transcriptio
n, DNA-
dependent
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formation at 
spindle pole 
during 
chromosom
e 
segregation
TIMP1 0.1 -0.7 0.4 -0.3 -0.3 -1.4 -0.5 -0.5 positive 
regulation 
of cell 
proliferation
TOP1 -0.9 -1.4 -1.8 -0.1 -0.4 -0.1 -0.4 -0.4 control of 
DNA 
topology 
during 
transcriptio
n
YWHAE 0.4 -1.2 0.4 -0.2 -0.1 -0.3 -1.2 -0.6 member of 
14-3-3 
family of 
proteins 
which 
mediate 
signal 
transductio
n
Apoptosis
AVEN 0.2 1.5 1.0 1.8 0.1 1.0 0.8 -0.2 inhibits 
Apaf-1-
mediated 
caspase 
activation
BAK1 -0.5 -0.8 -0.2 -0.6 -0.2 -0.1 0.7 -0.2 apoptosis 
promoter
BAX na na na na na na 0.5 -0.3 apoptosis 
promoter
BCL2 nd nd nd nd nd nd nd nd apoptosis 
inhibitor
BIRC5 -0.2 -1.2 nd 0.0 -0.1 -0.3 1.2 0.7 apoptosis 
inhibitor
BNIP3 na na na na na na -1.0 -0.1 apoptosis 
promoter
BNIP3L -1.3 -2.0 nd -2.0 -1.4 -1.0 -2.7 -0.5 apoptosis 
promoter
CASP3 0.0 -0.5 -1.7 -1.2 -0.3 -0.1 0.0 0.1 apoptosis 
promoter
FAS 2.1 3.8 2.9 3.3 1.8 2.2 0.2 0.2 apoptosis 
promoter
IRAK1 -0.7 -0.4 -0.4 -0.3 0.1 -0.1 1.6 0.1 apoptosis 
inhibitor
MALT1 na na na na na na 1.5 0.8 apoptosis 
inhibitor
SERPINB2 1.1 2.5 0.2 1.7 0.6 1.3 nd nd inhibits 
TNF-alpha-
induced 
apoptosis
TNFRSF6B na na na na na na -2.7 -2.0 apoptosis 
inhibitor
aLog2 ratios from 13 K cDNA microarrays (DNR) and b log2 ratios from 8.5 K oligonucleotide microarrays (Affymetrix).
na = gene not on array; nd = not detected; genes scored as up-regulated (log2 ratio ≥ 1) or down-regulated (log2 ratio ≤ -1) are in bold print.
c Information from NCBI Entrez Gene.
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DNA damage response and cell cycle-regulatory protein and transcript levels in 5-FU-treated parental and resistant HCT116 cell linesFigur  8
DNA damage response and cell cycle-regulatory protein and transcript levels in 5-FU-treated parental and 
resistant HCT116 cell lines: (a) p53 protein and TP53 transcript levels at 8 and 24 hours in 5-FU-treated HCT116 cell lines 
and their corresponding untreated controls; (b) GADD45A protein and transcript levels at 8 and 24 hours in 5-FU-treated 
HCT116 cell lines and their corresponding untreated controls; (c) CDKN1A protein and transcript levels at 8 and 24 hours in 
5-FU-treated HCT116 cell lines and corresponding untreated controls; (d) MYC protein and transcript levels at 8 and 24 hours 
in 5-FU-treated HCT116 cell lines and corresponding untreated controls. For the bar charts that present gene expression lev-
els, colorless bars depict the parental cell line, black bars the ContinB cell line, and vertically-striped bars the ContinD cell line.
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Molecular Cancer 2006, 5:20 http://www.molecular-cancer.com/content/5/1/20Table 2: Differential gene expression in parental HCT116 and 5-FU-resistant cell lines: additional affected regulatory pathways.
Gene 
symbol
par 8 hr 5 
FUa
par 24 hr 5 
FUa
ContinB 8 
hr 5 FU a
ContinB 24 
hr 5 FU a
ContinD 8 
hr 5 FU a
ContinB as 
a result of 5 
FU
altered in 
ContinD as 
a result of 
resistance 
developmen
t b
altered in 
ContinD as 
a result of 
resistance 
developmen
t b
Regulatory 
pathway/
function
Nucleoside
/nucleotide 
metabolism 
and 
nucleotide 
binding
ADSS -0.1 -1.4 0.1 -0.6 -0.2 -0.3 0.8 0.6 GTP and 
nucleotide 
binding; 
nucleotide 
metabolism
ATPIF1 -0.2 -1.0 0.4 -0.1 0.0 -1.5 na na negative 
regulation 
of 
nucleoside 
metabolism
ATAD2 -0.7 -0.5 -0.6 -0.6 -0.3 -1.2 na na ATP and 
nucleotide 
binding; 
assembly/
disassembly 
of protein 
complexes
CMPK 0.6 0.5 0.9 1.2 0.0 0.4 0.0 0.1 nucleobase, 
nucleoside, 
nucleotide 
and nucleic 
acid 
metabolism
GNL2 -0.2 0.3 -1.9 -1.2 -0.2 -0.2 0.2 0.1 nucleotide 
binding, 
protein 
binding, 
GTPase 
activity
GNL3 0.1 -0.2 -0.5 0.0 -0.4 -1.7 -0.5 -0.3 nucleotide 
binding, 
protein 
binding, 
GTPase 
activity
MATR3 -0.2 -0.8 -0.5 -1.4 -0.1 0.0 -0.6 -0.1 RNA 
binding; 
metal ion 
binding; 
nucleotide 
and nucleic 
acid binding
MBNL1 -1.0 -1.8 0.3 -0.3 -0.8 -0.4 na na nucleic acid 
binding; zinc 
ion binding
PRPS2 0.1 -0.3 -1.6 -1.2 0.0 -0.2 -0.2 -0.2 nucleoside 
metabolism; 
nucleotide 
biosynthesisPage 16 of 25
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e repeat 
containing 8 
gene – 
function 
unknown
mRNA 
processing/
transport
EPRS -0.3 -1.5 0.2 0.0 -0.7 -0.1 -0.9 -0.6 catalyzes 
aminoacylati
on of 
glutamic 
acid and 
proline 
tRNA 
species
GNB2 -0.5 -2.2 -0.3 -0.6 -0.1 0.3 0.1 -0.2 pre-mRNA 
processing 
and 
cytoskeleto
n assembly
HMG20B -0.6 -2.1 -0.7 -0.4 -0.2 -0.2 na na transcriptio
n factor; 
tRNA ligase 
activity; 
ATP binding
SRRM1 -0.6 -1.7 -0.4 -0.2 -0.3 -0.4 0.8 0.1 mRNA 
processing
STAU1 -0.3 -1.2 0.3 0.0 -0.1 -0.4 0.4 -0.1 mRNA 
transport; 
intracellular 
transporter 
activity
SYMPK -1.9 -0.9 -0.4 -0.8 -0.3 -0.3 0.3 -0.1 role in HSF1 
modulation 
of Hsp70 
mRNA 
polyadenylat
ion
THOC1 -0.5 -1.3 -0.5 -0.7 -0.1 -0.4 -0.3 0.4 regulates 
transcriptio
nal 
elongation; 
mRNA 
export from 
nucleus
Cytoskelet
on/cell 
motility/
cell 
adhesion
ACTG2 -0.1 -1.3 0.0 -0.6 -0.1 -0.4 nd nd maintenance 
of the 
cytoskeleto
n; cell 
motility
ARPC3 0.0 -1.2 -0.2 -0.6 0.2 -0.2 0.4 0.5 regulation 
of actin 
cytoskeleto
n
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of actin 
cytoskeleto
n; post-
translational 
modification 
of proteins
ILK -0.4 -0.3 0.0 0.7 0.1 -1.1 -0.2 -0.3 cell-matrix 
adhesion; 
integrin-
mediated 
signaling 
pathway
JUP -0.4 0.2 -1.1 -0.5 -0.1 1.1 -0.8 -0.3 cell 
adhesion
KRT7 0.1 0.4 0.8 1.4 0.3 0.4 na na cytoskeleto
n 
organization 
and 
biogenesis; 
cell 
communicat
ion
KRT8 0.3 0.1 1.0 1.7 0.3 0.6 na na cytoskeleto
n 
organization 
and 
biogenesis; 
cell 
communicat
ion
KRT19 0.3 0.7 1.0 1.7 -0.1 0.5 -0.3 -0.9 cytoskeleto
n 
organization 
and 
biogenesis; 
cell 
communicat
ion
MAST1 0.2 -0.7 -1.4 -1.3 0.1 0.2 na na cytoskeleto
n 
organization 
and 
biogenesis; 
protein 
amino acid 
phosphoryla
tion
TUBB 0.0 -0.3 0.5 0.3 -0.2 -1.3 na na microtubule
-based 
movement; 
protein 
polymerizati
on
TUBE1 -0.5 -0.6 0.3 -0.3 -0.3 -1.0 na na microtubule
-based 
movement; 
protein 
polymerizati
on
Amino 
acid, 
protein, 
carbohydra
te 
metabolism
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selenoamino 
acid 
metabolism
GANAB -0.2 -0.5 -1.4 -1.3 0.1 -0.2 na na carbohydrat
e 
metabolism
GCLC -0.5 -0.9 -2.2 -1.6 -0.2 -0.3 na na glutamate 
metabolism
GSS -0.3 -0.3 -1.8 -0.8 0.0 0.4 -0.2 -0.6 glutamate 
and 
glutathione 
metabolism
IVD -0.7 -0.2 -1.6 -2.4 -0.3 0.3 1.0 0.1 valine, 
leucine and 
isoleucine 
degradation
MRP63 0.7 0.6 1.4 1.1 0.2 0.0 na na protein 
synthesis 
within the 
mitochondri
on
OAT 0.1 -0.4 -1.9 -1.7 -0.1 0.0 -0.5 0.1 arginine and 
proline 
metabolism; 
ornithine 
metabolism
Signal 
transductio
n/transport
CENTG3 -1.1 0.2 -0.5 0.2 -0.6 1.1 na na regulation 
of GTPase 
activity; 
small 
GTPase 
mediated 
signal 
transductio
n
ERP70 -0.2 -1.9 -0.9 -0.4 -0.1 -0.3 na na electron 
transport 
and protein 
secretion
KPNA3 -0.8 -1.2 -0.1 -0.3 -0.3 -0.2 -0.1 -0.1 involved in 
nuclear 
transport 
system; 
intracellular 
protein 
transport
MTCH1 0.6 0.7 1.2 1.4 0.4 0.3 0.1 0.0 neuronal 
ion channel 
clustering; 
transport; 
regulation 
of signal 
transductio
n
NCBP1 -0.3 -0.6 -1.1 -1.0 0.0 -0.3 0.0 0.0 RNA 
splicing; 
mRNA 
nuclear 
export; 
mRNA 
processing; 
transport
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binding 
protein 
involved in 
protein 
transport
RAN -0.6 -0.8 -1.2 -1.6 0.0 -0.3 na na RNA and 
protein 
export from 
nucleus; 
small 
GTPase 
mediated 
signal 
transductio
n; 
intracellular 
protein 
transport
SLC16A1 0.2 -1.3 0.5 -0.5 -0.1 -0.7 -0.1 -0.5 mevalonate 
and organic 
anion 
transporter 
activity
SNAPAP -0.4 -0.9 -0.9 -1.6 -0.1 -0.2 na na exocytosis; 
intracellular 
protein 
transport; 
neurotrans
mitter 
secretion
TAX1BP1 -0.6 -0.1 0.6 0.6 0.2 -1.1 -1.3 -0.7 protein 
binding
TAX1BP3 -0.3 1.6 -0.1 0.0 0.3 -0.2 na na ATP 
binding; 
signal 
transductio
n; ion 
transport
TM9SF2 -0.4 -0.5 -1.9 -1.6 -0.1 -0.5 0.1 0.1 transport
TPD52 -0.4 -0.7 -1.8 -1.5 -0.3 -0.3 na na calcium ion 
binding; 
protein 
binding; 
protein 
homodimeri
zation 
activity; 
secretion
UFM1 -0.9 -0.4 -0.6 -1.5 0.1 0.3 na na ubiquitin 
cycle – 
function 
unknown
VPS52 -0.6 -1.2 0.1 -0.5 0.1 -0.2 0.3 -0.1 involved in 
vesicle 
trafficking 
from 
endosomes 
to trans-
Golgi 
network
Oxygen 
metabolism
COX5A 0.8 0.4 1.2 1.0 0.2 0.1 -0.1 -0.1 oxidative 
phosphoryla
tion
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phosphoryla
tion
MPV17 -0.3 0.5 -1.3 0.5 -0.4 0.9 -0.1 -0.1 oxygen and 
reactive 
oxygen 
species 
metabolism
SDHB -0.1 -0.7 -0.7 -1.6 0.1 -0.2 -0.1 -0.3 oxidative 
phosphoryla
tion; 
oxidative 
decarboxyla
tion of 
pyruvate 
and TCA 
cycle
a Log2 ratios from 13 K cDNA microarrays (DNR) and blog2 ratios from 8.5 K oligonucleotide microarrays (Affymetrix).
na = gene not on array; nd = not detected; genes scored as up-regulated (log2 ratio ≥ 1) or down-regulated (log2 ratio ≤ -1) are in bold print.
c Information from NCBI Entrez Gene.
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HCT116 cells at 24 hours. It also appeared that ContinD
cells had a higher tendency to arrest in G2. Cell counts
began to decrease immediately for parental and ContinB
cells following 5-FU removal from the media, whereas
this decrease was delayed by 24 hours for ContinD cells.
Decreases in cell numbers following drug removal were
consistent with cessation of mitotic activity at 24 hours
and with subsequent high levels of apoptosis (for parental
and ContinB cell lines) during recovery. The pattern of cell
cycle progression during recovery demonstrated consist-
ently that the smallest S phase fractions and the largest
G2(/M) fractions were measured in the 5-FU-resistant cell
lines.
The levels of apoptosis were dramatically lower in the
ContinD cell line relative to the other two cell lines, a pat-
tern that persisted throughout the recovery period. Since
this cell line also experiences a dramatic cell loss (>95%,
Figure 1), which is not the result of apoptosis, it may be
that cell death in this cell line occurs via necrosis. In any
event, this cell line had the fastest turnaround time, in that
it recovered exponential growth within 10 days, compared
to 20 days for the ContinB cell line and closer to 30 days
for the parental cell line.
The G1(/S) arrest in these cell lines was accompanied by
increases in p53 protein levels and induction of CDKN1A
transcripts and CDKN1A, suggesting that the arrest could
be p53-mediated. p53 is known to play a central role as a
mediator of the DNA damage response/cell cycle arrest
and in apoptosis induction [1,14,15]. There was little
agreement between p53 protein levels and TP53 transcript
levels, since the latter were either unchanged or down-reg-
ulated at 8 and 24 hours in each cell line. However, the
mechanism of p53 protein activation is by protein stabili-
zation (and phosphorylation) rather than by increased
transcription [4], and since these cell lines have wild-type
TP53 [10], and CDKN1A transcript and protein is induced
after irradiation with ionizing radiation (unpublished
results), the p53 response appears to be normal in the
resistant cell lines as well as in the parental cell line. 5-FU
treatment for 24 hours resulted in up-regulation of p53-
target genes on DNA damage response/repair (GADD45A,
XPC [16]PCNA [17], TP53I3, and ATF3), cell cycle-regula-
tory (CDKN1A), and apoptosis-regulatory pathways
(FAS) in the parental and resistant cell lines. Differential
down-regulation of cell-cycle regulatory genes known to
be repressed by p53, e.g. PLK, CCNB1, CCNB2 and TOP1
[18] was also demonstrated in these cell lines. Successful
detection of known p53-target genes by the microarrays
used in the present work indicated that we had a good sys-
tem for identifying p53-responsive genes. Apoptosis
induction also appeared to be p53-mediated, as the p53-
dependent apoptotic promoter FAS was up-regulated
[19,20] in these cell lines in response to 5-FU treatment.
Furthermore, induction of apoptosis is substantially
reduced in these cell lines following knockdown of p53
(manuscript in preparation).
Alterations in gene expression levels on cell cycle-, apop-
tosis-, and DNA damage response-regulatory pathways in
the present study provided little explanation for the differ-
ential resistance to 5-FU seen in the three cell lines, espe-
cially that seen in the ContinD cell line compared to the
other two cell lines. Many of the same genes were altered
in response to 5-FU in all three cell lines, with only small
differences in expression levels measured. Additionally,
some of the genes that were up-regulated in response to
short-term drug treatment had originally been down-reg-
ulated as a consequence of resistance development [10],
e.g. CDKN1A, GADD45A, and AREG (Table 1), underscor-
ing the difficulty in elucidating their role in/contribution
to an overall resistance phenotype and the intricacy of
drug resistance generally. However, when we considered
other cellular regulatory pathways that were affected in
response to short-term drug treatment, we found that
genes involved in nucleotide binding and nucleotide
metabolism, mRNA processing, cytoskeletal organization,
amino acid metabolism, signal transduction/transport,
and oxygen metabolism were differentially altered in the
three cell lines (Table 2). Some of the affected genes were
altered in the parental cell line but not in the resistant cell
lines (mRNA processing genes), or in one or both resistant
cell lines but not in the parental cell line (amino acid and
nucleotide metabolism genes). Such gene alterations may
provide important information about pathways that are
activated in response to 5-FU in cells that are already
resistant to the drug, information which may have useful
implications for the design and modification of current
chemotherapeutic regimens.
Conclusion
Our gene expression data suggest that altered regulation
of nucleotide metabolism, amino acid metabolism,
cytoskeleton organization, transport, and oxygen metabo-
lism may underlie the differential resistance to 5-FU seen
in these cell lines. Future work will involve RNA interfer-
ence studies to assess the contributory roles and impor-
tance of some of the altered genes to 5-FU resistance.
Methods
Cell lines, culture conditions, and drug treatment
The HCT116 parental cell line (ATCC CCL247) and
HCT116 ContinB and ContinD resistant derivatives (all
wild-type TP53 cell lines) were cultured in RPMI medium
with 10% heat-inactivated fetal calf serum, 2 mM
glutamine, and 0.6% Pen-Strep at 37°C in a humidified
atmosphere with 5% CO2. 5-FU was purchased from
Amersham Biosciences, England. HCT116 parental andPage 22 of 25
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per ml. in 6-well plates for cell cycle and apoptosis assays,
in 25 cm2 flasks for 5-FU incorporation measurements,
and 75 cm2 flasks for gene expression analyses. 770 μM 5-
FU was added to the media 24 hours after seeding. Cells
were harvested by trypsinization or scraping at 0, 8, and
24 hours after addition of 5-FU to the culture medium.
Control wells received no 5-FU. For gene expression anal-
yses, media was aspirated from exponentially-growing
parental and resistant HCT116 cell cultures, at 0 hours, 8
hours and 24 hours following addition of 770 μM 5-FU.
Control cell cultures (without 5-FU) were also harvested
at the same timepoints. Monolayers were harvested by
scraping and the cells frozen at -80°C until used for RNA
extraction.
Incorporation of 5-FU into DNA
HCT116 parental and resistant cells were seeded out at a
density of 1.0 × 105 cells per ml. in 25 cm2 flasks. Cells
were exposed to 5-FU for 24 hours as for the other assays,
except that the 5-FU solution contained 425 nM of [6-
3H]5-FU (Moravek Biochemicals Inc., Brea, CA). Control
wells received no 5-FU. Cells were harvested by scraping
at 8 and 24 hours after addition of 5-FU to the culture
medium, and frozen at -80°C until used for DNA extrac-
tion. DNA was extracted using standard phenol:chloro-
form:isopropyl alcohol procedures, precipitated with 7.5
M ammonium acetate and absolute ethanol, washed with
absolute ethanol, air-dried and then dissolved in Tris-
EDTA buffer, pH 8.0. DNA concentrations were measured
using absorbance spectrometry.
DNA samples were mixed into scintillation fluid and
measured in a Tri-carb Packard liquid scintillation counter
(Packard Instrument Co, Meriden, CT). Results are
expressed as the ratio of disintegrations per minute
(dpm): μg DNA.
Cell counts
Trypsinized cell suspensions were counted using a stand-
ard Trypan Blue viability assay. Cell counts were per-
formed at 0, 8, and 24 hours following addition of 5-FU
to the medium. For recovery assays, cell counts were also
done at successive 24-hour intervals until the cells had
regained exponential growth. After cell counting, the same
cell suspensions were then fixed in 80% ethanol for sub-
sequent cell cycle analyses.
Cell cycle analyses and quantification of apoptosis
Trypsinized cell suspensions were fixed in 80% ethanol.
The samples were then placed at -20°C until cell cycle
analysis. Nuclei were isolated from fixed cell suspensions,
stained with propidium iodide (50 μg/ml), and samples
analyzed for DNA content using a FACSCalibur laser flow
cytometer (Becton Dickinson Immunocytometry Systems,
San Jose, CA). Pulse-processed fluorescence signals were
used to exclude doublets and aggregates from analyses.
Ten thousand events were acquired for each sample. Per-
centages of cells in the G1, S, and G2M phases of the cell
cycle were quantified using WinCycle software (Phoenix
Flow Systems, San Diego, CA). Quantification of 5-FU-
induced apoptosis during treatment and recovery periods
in each cell line was done using the sub-G1 peaks from the
cell cycle analyses measured during these periods.
Mitotic cell discrimination
Percentages of mitotic cells in control and 5-FU-treated
cell cultures were determined using a flow cytometric
method to discriminate mitotic cells as described previ-
ously [21]. Trypsinized cell suspensions were centrifuged
at 1000 rpm for 5 minutes, washed once with PBS, and
resuspended in 750 μl of a cooled detergent buffer (0.1%
NP40, 6.5 mM Na2PO4, 1.5 mM KH2PO4, 2.7 mM KCl,
137 mM NaCl, 0.5 mM EDTA, pH7.2). After 5 min. on ice,
the cells were fixed by adding 250 μl 4% formaldehyde to
give a final concentration of 1%, mixed well, and allowed
to fix for a minimum of 1 hr. on ice. Samples were then
centrifuged at 1200 rpm for 5 minutes and the pellets
resuspended in the detergent buffer containing 5 μg/ml
propidium iodide and 100 μg/ml RNaseA. Samples were
analyzed on a FACSCalibur laser flow cytometer and per-
centages of mitotic cells were measured using correlated
DNA content/forward scatter distributions.
Microarray hybridization and data analysis
RNA isolation, preparation of Cy3- and Cy5- fluores-
cently-labeled cDNA samples, and subsequent hybridiza-
tion to 13 K microarrays were done as described
previously [22]. Thirty micrograms total RNA of control
and drug-treated cells were used for the Cy3- and Cy5-
labeled samples, respectively. The 13 K cDNA microarrays
were prepared at the Radiumhospital microarray core
facility, and information about them can be found at their
website [23]. Hybridized slides were scanned using a Scan
Array 4000 laser scanner at 10 μm resolution (Packard
BioChip Technologies, Billerica, MA). Spot and back-
ground intensities, and the standard deviations of these,
were quantified using Quantarray software (Packard Bio-
Chip Technologies). Bad spots and regions with high
unspecific binding of dye were manually flagged and
excluded from the analysis. Background-subtracted inten-
sities less than two times the standard deviation of the
local background were assigned this value to avoid zero or
negative values in the ratio calculations. Weak spots with
background-subtracted intensity less than two times the
standard deviation of the local background in both chan-
nels were excluded. Total intensity normalization of the
data was performed [24]. Genes in the 5-FU-treated
HCT116 cell lines that had two-fold expression level
changes (signal log2 ratios ≥ 1 or ≤ -1) relative to corre-Page 23 of 25
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scored as up-regulated or down-regulated respectively as a
result of drug treatment. At the 8 hour timepoint follow-
ing 5-FU addition, a total of 88, 99, and 10 genes were
scored as altered in HCT116 parental, ContinB, and Con-
tinD cells, respectively. At 24 hours, these numbers had
increased to 218, 323, and 89 for the ratios) for the same
cell lines. A text-tab-delimited file of all gene expression
data (log2 ratios) for the 5-FU-treated parental and drug-
resistant HCT116 cell lines (relative to their respective
untreated controls) is available upon request.
Gene expression data was sifted using GenMapp version
2.0 (Gene MicroArray Pathway Profiler) software [25].
Use of this program facilitated an immediate and compar-
ative overview of genes scored as up-regulated or down-
regulated (signal log2 ratios ≥ 1 or ≤ -1, respectively) on
specific pathways in response to 5-FU treatment in paren-
tal and 5-FU-resistant HCT116 cells. We focused on
altered genes located on DNA damage stimulus response,
cell cycle (general regulation, S phase and M phase regula-
tion) pathways and apoptosis regulatory pathways.
Real-time RT-PCR
Expression levels for 2 genes, GADD45A and CDKN1A
were determined by real-time RT-PCR for HCT116 paren-
tal, ContinB, and ContinD treated and untreated control
cells at all treatment timepoints using Taqman Gene
Expression Assays (Applied Biosystems, Foster City, CA).
200 ng of total RNA was subjected to real time RT-PCR
using an ABI PRISM Sequence Detection System following
manufacturer protocols, in order to confirm the 13 K
microarray results. Primers are available upon request.
The 18S gene was used as an endogenous control for equal
amounts of RNA used.
Western analyses
Scraped cell suspensions including floating cells that had
loosened from the monolayer during the course of 5-FU
treatment were centrifuged and the pellets heated in
standard Laemmli buffer containing PMSF. Protein con-
centrations were quantified (BioRad, Hercules, CA), and
protein samples (15 μg) and Precision Protein molecular
weight standards (6.5 μg, BioRad) were separated by SDS-
PAGE (10% or 12% gels) and transferred to PVDF mem-
branes (BioRad). Western blotting was performed using
mouse monoclonals against human p21WAF1 and p53
(clones EA10 and Pab1801, respectively, Calbiochem, San
Diego, CA), MYC (clone 6E10, Cambridge Research Bio-
chemicals, USA), GADD45A (C-4, Santa Cruz Biotechnol-
ogy, San Diego, CA) and actin (C-2, Santa Cruz
Biotechnology – used as a loading control). An amplified
alkaline phosphatase staining procedure (BioRad) was
used to detect the separated proteins. Expression levels
were quantified using UnScanIt gel software version 5.1
for Windows (Silk Scientific Inc., Orem, Utah).
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